New Publication Cites Improved Wound Healing Using MolecuLight Procedure Protection Status
Blog Category: 

By Industry News

Toronto, Canada – July 7 2021 – MolecuLight Inc., the creator of a point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of an independent consensus study of 32 leading wound care clinicians in Diagnostics.1 The publication, “Guidelines for point-of-care fluorescence imaging for detection of wound bacterial burden based on Delphi consensus”, presents the results of a Delphi consensus used to establish agreement on guidelines describing the use of fluorescence imaging for detection of elevated bacterial burden in wounds. In the study, a two-round Delphi process was employed amongst a multidisciplinary panel of 32 wound experts across multiple sites of service including hospital outpatient, inpatient, private office and long-term care residences. The result was that 96% of clinicians reported that treatment plans informed by the MolecuLight procedure led to improved wound healing. The agreed-upon guidelines will help to standardize the use of fluorescence imaging using the MolecuLight i:X among wound care providers and enhance the quality of patient care.

In addition to guidelines on when and how frequently the MolecuLight imaging procedure should be performed, notable findings describing the impact of the MolecuLight i:X on clinical experiences include:

  • >80% of clinicians reported changes in treatment plans,
  • 96% reported that imaging-informed treatment plans led to improved wound healing,
  • 78% reported reduced rates of amputations, and
  • 83% reported reduced rates of microbiological sampling.

“The results of the Delphi survey show an incredibly high level of agreement (>85%) across a wide variety of leading wound care professionals”, says Dr. Thomas Serena, the publication’s senior author and Founder and Medical Director of The SerenaGroup®.

“The use of this imaging procedure enables health care providers to rapidly detect elevated levels of bacteria and to develop an effective treatment plan while at the same time avoiding the use of advanced therapies when they are contradicted." says Martha R. Kelso RN, LNC, HBOT, contributing author of the publication, and Founder and Chief Executive Officer of Wound Care Plus, LLC. "In addition to improving patient outcomes, this technology has high potential to reduce the overuse of antimicrobials and reduce health care costs for both patients and health systems”.

A key outcome of the Delphi consensus was the development of a clinical workflow for fluorescence imaging of elevated bacterial loads. This workflow describes how to most effectively leverage imaging of bacterial burden to enhance wound hygiene and better inform treatment planning based on objective point-of-care information on wound bioburden. It also serves to improve the consistency of care across the wound care continuum.

Authors of the publication will participate in a panel discussion webinar entitled “When should I perform point-of-care fluorescence imaging of wound bioburden? Guidelines based on Delphi consensus”. In this session, authors will review the study findings and discuss why they believe fluorescence imaging of elevated bacterial burden is an essential procedure in their wound care. The webinar will be held on July 27, 2021 at 1:00 pm EST. To register, visit

The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, HMP Global, its affiliates, or subsidiary companies.

Related company: 

Recommended for You

Important Notice: The contents of the website such as text, graphics, images, and other materials contained on the website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The content is not intended to substitute manufacturer instructions. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or product usage. Refer to the Legal Notice for express terms of use.